Study to Assess SLN124 in Patients With Polycythemia Vera

Summary

This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety, tolerability, efficacy, pharmacokinetic (PK), and Pharmacodynamic (PD) response of SLN124.

Timeline

Start

2023-01-26

Primary completion

2026-09

Completion

2030-03

Drugs

Indications